Pirfenidone Tablet
Product Images NDC 50228-442

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Pirfenidone (NDC 50228-442). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sciegen Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Pirfenidone 02)

This chart compares the percentage of patients with absolute change in %FVC (Forced Vital Capacity) from baseline to Week 52 between Pirfenidone (n=278) and Placebo (n=277). It shows the distribution of patients experiencing worsening (decrease in %FVC) versus no decline (increase in %FVC) outcomes.*

FDA Label Image

Figure 2 (Pirfenidone 03)

A line graph depicting the mean change in forced vital capacity (FVC) in milliliters over 52 weeks. It compares two groups: one treated with Pirfenidone and the other with a placebo. Both groups show a decline in FVC, with the placebo group experiencing a steeper decline over time.*

FDA Label Image

Figure 3 (Pirfenidone 04)

A survival curve chart comparing percentage of patients alive over time (in weeks) between Pirfenidone (n=623) and placebo (n=624) groups. The solid line represents Pirfenidone and the dashed line represents placebo. The chart includes a hazard ratio (HR) with 95% confidence interval (CI) of 0.75 (0.51–1.11) and displays numbers of patients at risk at various time points for both groups.*

FDA Label Image

Principal Display Panel (267 mg 30 Tablets)

Label for Pirfenidone Tablets 267 mg by ScieGen Pharmaceuticals, Inc., Hauppauge, NY. The oral tablet packaging contains 30 film-coated tablets. The label includes storage instructions to keep at 25°C (77°F) with allowed excursions and a notice to keep out of reach of children. The NDC number 50228-442-30 and barcode are visible.*

FDA Label Image

Principal Display Panel (267 mg 1,000 Tablets)

Label for Pirfenidone Tablets 267 mg oral tablets by ScieGen Pharmaceuticals, Inc. The label indicates a package size of 1,000 tablets. It includes storage instructions, dosage reference, NDC number, and manufacturer address. The label also notes no varnish on the product packaging.*

FDA Label Image

Principal Display Panel (801 mg 30 Tablets)

Label for Pirfenidone Tablets 801 mg, oral tablets supplied by ScieGen Pharmaceuticals, Inc. The label states each film-coated tablet contains 801 mg pirfenidone. It includes storage instructions, a barcode, and indicates the package contains 30 tablets, Rx only.*

FDA Label Image

Principal Display Panel (801 mg 500 Tablets)

Label for Pirfenidone Tablets, 801 mg oral tablets by ScieGen Pharmaceuticals, Inc. The label lists the strength as 801 mg with a package size of 500 tablets. Storage instructions specify 25°C with allowed excursions, and it includes a barcode along with the NDC number 50228-443-05. The label also notes that the product is Rx only and includes space for lot and expiration date.*

FDA Label Image

Chemical Structure (Pirfenidone Str 01)

Chemical structure of pirfenidone showing a pyridone ring bonded to a phenyl group with a methyl substituent on the pyridone ring.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.